New tools to monitor stress using non-invasive PET imaging

Annals of the New York Academy of Sciences

Volumn 1018, Issue , 2004, Pages 487-494

  Eckelman, William C ^a   Rice, Kenner C ^b   Contoreggi, Carlo ^c  

^a NATIONAL INSTITUTES OF HEALTH   (United States)

^b NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES   (United States)

^c NATIONAL INSTITUTES OF HEALTH   (United States)

Author keywords

Chemotherapy; Chronic myelogenous leukemia; Gastrointestinal stromal tumors; Imaging; Positron emission tomography; Tyrosine kinase

Indexed keywords

CARBON 11; CORTICOTROPIN RELEASING FACTOR; DOPAMINE; FLUORINE 18; MUSCARINIC RECEPTOR; N [2 [4 (2 METHOXYPHENYL) 1 PIPERAZINYL]ETHYL] N (2 PYRIDYL)CYCLOHEXANECARBOXAMIDE; PROTEIN TYROSINE KINASE; SEROTONIN; UNCLASSIFIED DRUG;

CONFERENCE PAPER; DOPAMINERGIC SYSTEM; NEUROCHEMISTRY; NEUROTRANSMISSION; NONHUMAN; POSITRON EMISSION TOMOGRAPHY; SEROTONINERGIC SYSTEM; STRESS;

EID: 3242685955     PISSN: 00778923     EISSN: None     Source Type: Book Series    
DOI: 10.1196/annals.1296.060     Document Type: Conference Paper

References (30)

1. FRANCIS, S., et al. 2003. A vision for the future of genomics research. Nature 422: 835-847.
2. PHELPS, M.E. 2000. PET: the merging of biology and imaging into molecular imaging. J. Nucl. Med. 41: 661-681.
3. DEMETRI, G.D., et al. 2002. Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N. Engl. J. Med. 347: 472-480.
4. ECKELMAN, W.C. 2002. Accelerating drug discovery and development through in vivo imaging. Nucl. Med. Biol. 29: 777-782.
5. VAN DEN ABBEELE, A.D. & R.D. BADAWI. 2002. Use of positron emission tomography in oncology and its potential role to assess response to imatinib mesylate therapy in gastrointestinal stromal tumors (GISTs). Eur. J. Cancer 38(Suppl. 5): S60-S65.
6. HOOD, L. & D. GALAS. 2003. The digital code of DNA. Nature 421: 444-448.
7. CHROUSOS, G.P. 1998. Stressors, stress, and neuroendocrine integration of the adaptive response. The 1997 Hans Selye Memorial Lecture. Ann. N.Y. Acad. Sci. 851: 311-335.
8. KOOB, G.F. 1999. Corticotropin-releasing factor, norepinephrine, and stress. Biol. Psychiatry 46: 1167-1180.
9. JAGODA, E., et al. 2003. Autoradiographic visualization of corticotropin releasing hormone type 1 receptors with a non-peptide ligand: synthesis of [76Br]MJL-1-109-2. J. Med. Chem. 46: 3559-3562.
10. 2A) positron emitting ligand, MDL 100,907. Proc. Natl. Acad. Sci. USA (Submitted).
11. LANG, L., et al. 1999. Development of fluorine-18-labeled 5-HT1A antagonists. J. Med. Chem. 42: 1576-1586.
12. CARSON, R.E., et al. 2000. PET evaluation of [(18)F]FCWAY, an analog of the 5-HT(1A) receptor antagonist, WAY-100635. Nucl. Med. Biol. 27: 493-497.
13. LANG, L., et al. 2000. Fluoro analogs of WAY-100635 with varying pharmacokinetics properties. Nucl. Med. Biol. 27: 457-462.
14. LARUELLE, M. & Y. HUANG. 2001. Vulnerability of positron emission tomography radiotracers to endogenous competition. Q. J. Nucl. Med. 45: 124-138.
15. HIGHFIELD, D., et al. 2001. Repeated lofexidine treatment attenuates stress-induced, but not drug cues-induced reinstatement of a heroin-cocaine mixture (speedball) seeking in rats. Neuropsychopharmacology 25: 320-331.
16. BREIER, A., et al. 1997. Schizophrenia is associated with elevated amphetamine-induced synaptic dopamine concentrations: evidence from a novel positron emission tomography method. Proc. Natl. Acad. Sci. USA 94: 2569-2574.
17. VOLKOW, N.D., et al. 1999. Association of methylphenidate-induced craving with changes in right striato-orbitofrontal metabolism in cocaine abusers: implications in addiction. Am. J. Psychiatry 156: 19-26.
18. VOLKOW, N.D., et al. 1997. Decreased striatal dopaminergic responsiveness in detoxified cocaine-dependent subjects. Nature 386: 830-833.
19. KOOB, G.F. 2000. Neurobiology of addiction. Toward the development of new therapies. Ann. N. Y. Acad. Sci. 909: 170-185.
20. KOOB, G.F. 1999. Stress, corticotropin-releasing factor, and drug addiction. Ann. N.Y. Acad. Sci. 897: 27-45.
21. DILSAVER, S.C. 1988. Effects of stress on muscarinic mechanisms. Neurosci. Biobehav. Rev. 12: 23-28.
22. DILSAVER, S.C., et al. 1990. Chronic swim stress enhances the motoric inhibiting effects of a muscarinic agonist. Pharmacol. Biochem. Behav. 37: 213-217.
23. KIESEWETTER, D.O., et al. 1995. Preparation of 18F-labeled muscarinic agonist with M2 selectivity. J. Med. Chem. 38: 5-8.
24. 18F]FP-TZTP: control and competition studies. J. Cereb. Blood Flow Metab. 18: 1130-1142.
25. KIESEWETTER, D.O., et al. 1999. In vivo muscarinic binding of 3-(alkylthio)-3-thiadiazolyl tetrahydropyridines. Synapse 31: 29-40.
26. JAGODA, E.M., et al. 2003. Regional brain uptake of the muscarinic ligand, [(18)F]FP-TZTP, is greatly decreased in M2 receptor knockout mice but not in M1, M3 and M4 receptor knockout mice. Neuropharmacology 44: 653-661.
27. 18F]FP-TZTP binding by loading doses of muscarinic agonists P-TZTP or FP-TZTP in vivo is not due to agonist-induced reduction in cerebral blood flow. Synapse 50: 151-163.
28. PODRUCHNY, T.A., et al. 2003. In vivo muscarinic 2 receptor imaging in cognitively normal young and older volunteers. Synapse 48: 39-44.
29. COHEN, R.M., et al. 2003. Higher in vivo muscarinic-2 receptor distribution volumes in aging subjects with an apolipoprotein E-epsilon4 allele. Synapse 49: 150-156.
30. 18F-MPPF in the rat hippocampus: kinetic beta measurements combined with microdialysis. J. Neurochem. 80: 278-286.